Natco Pharma gets FDA approval for Lenalidomide Capsules
Natco Pharma has secured the final approval from the US Food and Drug Administration (FDA) of its abbreviated new drug application (ANDA) for Lenalidomide Capsules, ... Read More
BMS, bluebird bio bag Abecma FDA approval for multiple myeloma in adults
Abecma FDA approval : Bristol Myers Squibb (BMS) and bluebird bio have secured approval from the US Food and Drug Administration (FDA) for Abecma (idecabtagene ... Read More
OncoSec Medical begins phase 2 trial for TAVO and OPDIVO combination in melanoma treatment
OncoSec Medical, a US-based biotechnology company, has officially dosed the first patient in its phase 2 clinical trial, OMS-104, aimed at evaluating the combination of ... Read More
BMS gets Opdivo EC approval for second-line treatment of ESCC
Opdivo EC approval : Bristol Myers Squibb (BMS) has secured approval from the European Commission (EC) for its immunotherapy Opdivo (nivolumab) as a second-line treatment ... Read More
Bristol Myers Squibb wraps up $13.1bn acquisition of MyoKardia
Bristol Myers Squibb has wrapped up its previously announced $13.1 billion acquisition of MyoKardia, a California-based clinical-stage biopharma company. Following the closing of the deal, ... Read More
BMS’ Zeposia succeeds in True North clinical trial in ulcerative colitis
Bristol Myers Squibb (BMS) said that the phase 3 True North clinical trial evaluating Zeposia (ozanimod) in adult patients with moderate to severe ulcerative colitis ... Read More
Bristol Myers Squibb to acquire MyoKardia to gain access to mavacamten
Bristol Myers Squibb (BMS) has agreed to acquire California-based clinical-stage biopharma company MyoKardia for $13.1 billion, to gain access to the latter’s cardiovascular drug candidate ... Read More
FDA approves BMS’ Opdivo, Yervoy combo for malignant pleural mesothelioma
Bristol Myers Squibb (BMS) has secured approval for Opdivo (nivolumab) and Yervoy (ipilimumab) combination from the US Food and Drug Administration (FDA) for the first-line ... Read More
EC approves Reblozyl for transfusion-dependent anemia in adults
Bristol Myers Squibb and Acceleron Pharma have secured approval from the European Commission (EC) for their jointly developed erythroid maturation agent Reblozyl (luspatercept) for the ... Read More
Bristol-Myers Squibb wraps up $74bn acquisition of Celgene
Bristol-Myers Squibb has wrapped up its $74 billion acquisition of Celgene having got regulatory approval from all government authorities necessary for closing the merger agreement ... Read More